Navigation Links
FDA gives “black box warning” against three asthma drus

Food and Drug Administration has given a “black box warning” to three asthma drugs//, Foradil, Adavir and Serevent. The FDA panel has advised the manufacturers that the drug should carry clearly the warnings regarding the risks for worsened breathing.

Adavir and Serevent are manufactured by Glaxosmithkline, which contains a compound Salmeterol. Novartis manufacturers the drug Foradil which contains a different long-acting beta-agonist. The U.S. Advisory panel has advised Novartis that they should carry the warnings as mentioned by GlaxosmithKline in their drug Adavir and Serevent.

The resolution of the FDA panel said that consumers and doctors have to know more information about the potential risk of Foradil’s. ``There is information that should come forward'' on potential Foradil risk, said Nancy Sander, an FDA panelist. FDA is reviewing the drugs and advising the pharmaceutical industries to provide more information to the consumers since the withdrawal of Vioxx painkiller of Merck & Co., from the market in September.

Asthma causes inflammation in the airways of the lung leading to lung muscle constriction leading to difficulty in breathing. Though, the FDA panel has approved the stay of Serevent, Adavir and Foradil in the market they insist the drugs should carry additional warnings. Advair and Serevent drugs were both combined with a corticosteroid for better treatment against asthma; the total sales of both these drugs were 2.5 million pounds (4.4 billion dollars).

SMART trial conducted in 1996 by Glaxo on their two drugs Serevent and Adavir was done as advised by FDA. The SMART trial was done with 26,000 recruits and the study was stopped in 2003 after about 50 people died or had severe life-threatening breathing complications after taking Serevent compared with placebo. In the study 20 black people had serious complications or died compared to 5 taking placebo. Though these results should not give misleading conception that blacks should not take the drug. These studies give a clear warning to the consumers about the drug. The pharmaceutical companies should give clear indications about the test results in a clearly understandable way by tabulating and by graphs.

Asthma patients should not stop taking their asthma medications without talking to their doctor. Abruptly stopping asthma medication can result in an asthma attack.

Research of Novartis has found a potential risk for worsened breathing with a higher dose of Foradil than the dosage allowed in the U.S., the FDA said in its review
'"/>




Related medicine news :

1. Microchip gives blind a chance of sight
2. Microchip gives blind a chance of sight
3. Combined scan gives exact cancer diagnosis
4. Tennis gives protection against heart disease lifelong
5. Camera gives hope for detection of breast cancer
6. Pancreas transplant gives hope to type 2 diabetes
7. Trust in Doctor gives better cure
8. Wonder drug Dasatinib gives hopes to leukemia patients
9. 5 Year Old Paralyzed Victim Forgives 50 Year Old Man Who Shot Her
10. ‘Aricept’ drug gives an Alzheimer’s patient reason to smle
11. LA County gives Approval for Reform Plan for King-Drew Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/27/2017)... ... April 27, 2017 , ... The ... Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of how behavioral economics ... takeaways to apply immediately to IRR programs, the report highlights proven behavioral economics ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins ... the Year for her extraordinary compassion and lifelong dedication to serve others. Since ... caregivers for the prestigious award each year – identifying a CAREGiver who has ...
(Date:4/27/2017)... ... , ... Are you investing in the safety of your friends and family? ... summer. While most of us assume this type of accident will never happen to ... are taking the time to learn how to respond effectively or prevent these accidents ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Journal ... adults. It can have severe consequences to overall dental health, including complications with speech, ... often turn to dental implants to replace lost teeth. As the number of tooth ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and ... by Enterprising Women magazine as one of its 2017 Enterprising Women of the ... Winners have demonstrated that they have fast-growth businesses, mentor or actively support other ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
Breaking Medicine Technology: